Nonalcoholic Fatty Liver Disease Serum
Nonalcoholic Fatty Liver Disease Serum is collected from IRB-consented donors with confirmed NAFLD. Useful for evaluating liver enzymes, lipid profiles, adipokines, insulin resistance markers, and fibrosis-related proteins. Available stratified by steatosis versus steatohepatitis and fibrosis stage, with matched healthy controls.
Nonalcoholic Fatty Liver Disease Serum for Metabolic Liver Disease Research
Our Nonalcoholic Fatty Liver Disease Serum is sourced from IRB-consented donors clinically diagnosed with nonalcoholic fatty liver disease (NAFLD). Each sample is processed and frozen within 24 hours of collection to preserve enzymes, lipids, adipokines, and other labile analytes. Serum is acellular, so this product is intended for soluble-analyte measurement rather than cell-based assays.
NAFLD Metabolic Biology and Why Serum
NAFLD is a metabolic liver disease. It is not autoimmune. The disease begins with excess triglyceride accumulation in hepatocytes and is tightly coupled to insulin resistance and adipose tissue dysfunction.
- Hepatic steatosis develops when fatty acid delivery and de novo lipogenesis exceed oxidation and export, driven in large part by peripheral and hepatic insulin resistance
- Lipotoxicity from specific lipid species, rather than triglyceride storage alone, is thought to drive hepatocyte stress, injury and cell death
- A subset of donors progress from simple steatosis to steatohepatitis, with hepatocyte ballooning, lobular inflammation and metabolic inflammation involving resident and recruited immune cells
- Ongoing injury activates hepatic stellate cells, producing progressive fibrosis that can advance to cirrhosis and is the strongest predictor of clinical outcome
- Serum carries the analytes used to track all of this non-invasively: aminotransferases (ALT, AST), gamma-glutamyl transferase, adipokines, lipid panels and lipid species, glucose and insulin, ferritin, and extracellular matrix turnover markers
- Serum is a standard matrix for the routine chemistry and multi-analyte fibrosis scores that are widely used in place of repeat biopsy
Donor Stratification Available
- Simple steatosis versus nonalcoholic steatohepatitis where histologically or clinically characterised
- Fibrosis stage or non-invasive fibrosis score where available
- Presence or absence of comorbid type 2 diabetes
- BMI and obesity class
- Method of diagnosis: imaging, elastography, or liver biopsy
- Comorbid dyslipidaemia, hypertension, or metabolic syndrome
- Matched healthy controls available
Product Features
- Collected from clinically confirmed NAFLD donors
- Research Use Only (RUO)
- Processed and frozen within 24 hours of collection
- IRB-approved protocols with documented consent
- Custom aliquot volumes available upon request
De-identified Donor Data
- Diagnosis confirmation
- Age, sex assigned at birth, race/ethnicity, and BMI
- Donor-reported medical history, medications, and comorbidities
- Liver function test results where available
- Additional NAFLD-specific metadata available on request
Applications
- Non-invasive fibrosis biomarker discovery and validation
- Liver enzyme and hepatic injury marker studies
- Insulin resistance and adipokine profiling
- Serum lipidomics and untargeted metabolomics
- Extracellular matrix turnover marker measurement
- Metabolic inflammation cytokine profiling
- Serum proteomics for steatohepatitis versus simple steatosis discrimination
- Diagnostic assay and multi-analyte panel development, and therapeutic response research for metabolic liver disease candidates
Other Nonalcoholic Fatty Liver Disease Specimen Types
- Nonalcoholic Fatty Liver Disease Plasma
- Nonalcoholic Fatty Liver Disease Whole Blood
- Nonalcoholic Fatty Liver Disease PBMC
- Nonalcoholic Fatty Liver Disease Leukopak
- Nonalcoholic Fatty Liver Disease Bulk Plasma
- Nonalcoholic Steatohepatitis Whole Blood
Compliance and Quality Assurance
- IRB-approved and HIPAA-compliant protocols
- Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
- Documentation support available for regulatory review
Ordering & Customization
Nonalcoholic Fatty Liver Disease serum is available in standard and custom volumes. For pricing, availability, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To browse serum from other disease states and check live stock status, visit our human serum page.
Protocols & Documentation
-
Download
Serum Isolation
Protocol for serum preparation from whole blood, including collection handling, clarification, and quality documentation.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Serum
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – all our products are research use only (RUO).
1 Answer
You can find our full product catalog here.
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: Quality and Compliance
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom Serum cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.